These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35613944)

  • 21. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
    J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
    Pennisi G; Enea M; Falco V; Aithal GP; Palaniyappan N; Yilmaz Y; Boursier J; Cassinotto C; de Lédinghen V; Chan WK; Mahadeva S; Eddowes P; Newsome P; Karlas T; Wiegand J; Wong VW; Schattenberg JM; Labenz C; Kim W; Lee MS; Lupsor-Platon M; Cobbold JFL; Fan JG; Shen F; Staufer K; Trauner M; Stauber R; Nakajima A; Yoneda M; Bugianesi E; Younes R; Gaia S; Zheng MH; Cammà C; Anstee QM; Mózes FE; Pavlides M; Petta S
    Hepatology; 2023 Jul; 78(1):195-211. PubMed ID: 36924031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
    Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
    World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.
    Mózes FE; Lee JA; Vali Y; Alzoubi O; Staufer K; Trauner M; Paternostro R; Stauber RE; Holleboom AG; van Dijk AM; Mak AL; Boursier J; de Saint Loup M; Shima T; Bugianesi E; Gaia S; Armandi A; Shalimar ; Lupșor-Platon M; Wong VW; Li G; Wong GL; Cobbold J; Karlas T; Wiegand J; Sebastiani G; Tsochatzis E; Liguori A; Yoneda M; Nakajima A; Hagström H; Akbari C; Hirooka M; Chan WK; Mahadeva S; Rajaram R; Zheng MH; George J; Eslam M; Petta S; Pennisi G; Viganò M; Ridolfo S; Aithal GP; Palaniyappan N; Lee DH; Ekstedt M; Nasr P; Cassinotto C; de Lédinghen V; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Fournier-Poizat C; Geier A; Martic M; Tuthill T; Anstee QM; Harrison SA; Bossuyt PM; Pavlides M;
    Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):704-713. PubMed ID: 37290471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
    Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
    Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study.
    Besutti G; Bonilauri L; Manicardi E; Venturelli F; Bonelli E; Monelli F; Manicardi V; Valenti L; Ligabue G; Schianchi S; Massari M; Riva N; Froio E; Tagliavini E; Pattacini P; Giorgi Rossi P
    Diabetes Res Clin Pract; 2021 Jul; 177():108882. PubMed ID: 34082056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approach to the Patient With Nonalcoholic Fatty Liver Disease.
    Belfort-DeAguiar R; Lomonaco R; Cusi K
    J Clin Endocrinol Metab; 2023 Jan; 108(2):483-495. PubMed ID: 36305273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis: A cross-sectional study.
    Bhadoria AS; Kedarisetty CK; Bihari C; Kumar G; Jindal A; Bhardwaj A; Shasthry V; Vyas T; Benjamin J; Sharma S; Sharma MK; Sarin SK
    Liver Int; 2017 Sep; 37(9):1397-1404. PubMed ID: 28231412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type 2 diabetes complications are associated with liver fibrosis independent of hemoglobin A1c.
    Trivedi HD; Tran Q; Fricker Z; Curry MP; Li JX; Lai M
    Ann Hepatol; 2023; 28(3):101087. PubMed ID: 36882138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
    Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced liver fibrosis and the metabolic syndrome in a primary care setting.
    Schreiner AD; Zhang J; Durkalski-Mauldin V; Livingston S; Marsden J; Bian J; Mauldin PD; Moran WP; Rockey DC
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3452. PubMed ID: 33759300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study.
    Ishiba H; Sumida Y; Tanaka S; Yoneda M; Hyogo H; Ono M; Fujii H; Eguchi Y; Suzuki Y; Yoneda M; Takahashi H; Nakahara T; Seko Y; Mori K; Kanemasa K; Shimada K; Imai S; Imajo K; Kawaguchi T; Nakajima A; Chayama K; Saibara T; Shima T; Fujimoto K; Okanoue T; Itoh Y;
    J Gastroenterol; 2018 Nov; 53(11):1216-1224. PubMed ID: 29744597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes Liver Fibrosis Score to Detect Advanced Fibrosis in Diabetics with Nonalcoholic Fatty Liver Disease.
    Singh A; Garg R; Lopez R; Alkhouri N
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e624-e626. PubMed ID: 33434655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of Simple Fibrosis Score in Non-Alcoholic Fatty Liver Disease with and without Type 2 Diabetes.
    Chung SM; Kang MK; Moon JS; Park JG
    Endocrinol Metab (Seoul); 2023 Apr; 38(2):277-281. PubMed ID: 36914242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study).
    Collier A; Curran C; Cameron L; Wild SH; Byrne CD
    Diabetes Obes Metab; 2023 Sep; 25(9):2659-2668. PubMed ID: 37311724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes.
    Noureddin N; Noureddin M; Singh A; Alkhouri N
    Dig Dis Sci; 2022 Apr; 67(4):1379-1388. PubMed ID: 33779880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Kobayashi N; Kumada T; Toyoda H; Tada T; Ito T; Kage M; Okanoue T; Kudo M
    Dig Dis; 2017; 35(6):521-530. PubMed ID: 29040984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.